Bristol Myers Squibb raised its full-year revenue forecast while lowering 2026 EPS due to an acquisition charge, driven by strong sales of newer medicines. Third-quarter revenue rose 7% to $13.1 billi
A new hydrocarbon scaffold named mousane has been developed to add rigidity to drug candidates, potentially improving their properties. The research, published as a preprint, was led by teams from Bri
Bristol Myers Squibb raised its full-year revenue and profit forecast after second-quarter results exceeded Wall Street estimates, driven by strong sales of Eliquis and newer medicines like Camzyos an
Bristol Myers Squibb partners with Anthropic to deploy Claude AI across 30,000 employees to accelerate drug discovery and manufacturing. The initiative aims to leverage agentic AI to potentially boost
Bristol Myers Squibb has partnered with Chinese drugmaker Hengrui Pharmaceuticals in a deal potentially worth up to $15.2 billion, featuring a $600 million upfront payment and milestone options.
Bristol Myers Squibb exceeded Q1 profit expectations on strong Eliquis and cancer drug sales, boosting shares 4%. It reaffirmed its 2026 outlook and intends to leverage AI to accelerate drug discovery
ChemBrief